Literature DB >> 14691215

An in vitro human cell-based assay to rank the relative immunogenicity of proteins.

Marcia Stickler1, Narapon Rochanayon, O Jennifer Razo, Jeanette Mucha, Wendy Gebel, Nargol Faravashi, Regina Chin, Susan Holmes, Fiona A Harding.   

Abstract

A method to rank proteins based on their relative immunogenicity has been devised. A statistical analysis of peptide-specific responses in large human donor pools provides a structure index value metric that ranked four industrial enzymes in the order determined by both mouse and guinea pig exposure models. The ranking method also compared favorably with human sensitization rates measured in occupationally exposed workers. Structure index values for other proteins known to cause immune responses in humans were also determined and found to be higher than the value determined for human beta2-microglobulin. Using values from known immunogenic and putative nonimmunogenic proteins, a cut-off value was established. The structure index value calculation provides a comparative method to predict subsequent immunogenicity on a human population basis without the need to use animal models. Information provided by this assay can be used in the early development of protein therapies and other protein-based applications to select or create reduced immunogenicity variants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14691215     DOI: 10.1093/toxsci/kfh021

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  6 in total

1.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

Authors:  Matthew P Baker; Helen M Reynolds; Brooke Lumicisi; Christine J Bryson
Journal:  Self Nonself       Date:  2010-10

2.  Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.

Authors:  Srivalli Telikepalli; Heather E Shinogle; Prem S Thapa; Jae Hyun Kim; Meghana Deshpande; Vibha Jawa; C Russell Middaugh; Linda O Narhi; Marisa K Joubert; David B Volkin
Journal:  J Pharm Sci       Date:  2015-03-05       Impact factor: 3.534

3.  Antibacterial efficacy of R-type pyocins towards Pseudomonas aeruginosa in a murine peritonitis model.

Authors:  Dean Scholl; David W Martin
Journal:  Antimicrob Agents Chemother       Date:  2008-03-10       Impact factor: 5.191

4.  Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

Authors:  Masanori Onda; Richard Beers; Laiman Xiang; Byungkook Lee; John E Weldon; Robert J Kreitman; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 12.779

5.  Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay.

Authors:  Heidi S Schultz; Stine Louise Reedtz-Runge; B Thomas Bäckström; Kasper Lamberth; Christian R Pedersen; Anne M Kvarnhammar
Journal:  PLoS One       Date:  2017-05-31       Impact factor: 3.240

6.  T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.

Authors:  Vibha Jawa; Frances Terry; Jochem Gokemeijer; Shibani Mitra-Kaushik; Brian J Roberts; Sophie Tourdot; Anne S De Groot
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.